Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
The SISTER study is a randomized trial, looking at various modalities of social support for Black patients undergoing treatment for endometrial cancer. There are three study arms: group support, 1:1 peer support, and enhanced usual care. The primary outcome is treatment completion, and the secondary outcome is social isolation.
Full description
SISTER is a prospective, open randomized controlled trial of U.S. Black/African-American people with high-risk endometrial cancer requiring treatment with chemotherapy, radiation, or immunotherapy. We will compare social support interventions of enhanced usual care, weekly group-based support, and 1:1 peer support to determine the most effective option to improve treatment completion and decrease social isolation.
The SISTER study comparators are based on multiple systematic reviews of peer support literature, input from the multi-stakeholder Steering Group of the Endometrial Cancer Action Network for African Americans (ECANA), two focus groups of Black women with EC, and cancer center leadership at selected enrollment sites. The core function of each comparator is to decrease social isolation for women on active treatment. Of the peer support intervention options available, the SISTER study includes the two that have the most data collected among Black women with cancer, have been most efficacious with regard to social isolation9 and treatment completion, and were enthusiastically supported by ECANA patient partners and focus group data.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Adult 18 years of age or older; and
Self-identify as Black/African American
Presenting with high-risk EC established by anatomic pathology as tumor stage and grade classification by the following:
Documented provider recommendation and patient plan to initiate adjuvant therapy with chemotherapy, radiation, and/or immunotherapy.
Exclusion criteria
Participants must not have any of the following exclusion criteria:
Primary purpose
Allocation
Interventional model
Masking
252 participants in 3 patient groups
Loading...
Central trial contact
Kemi M Doll, MD, MS; SISTER team
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal